RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.